 |
|
|
| |
Impact of PegIntron (PEG) Maintenance Therapy (MT) on Fibrosis Biomarkers (FibroTest [FT]/FibroSURE) in Prior Nonresponders With METAVIR Fibrosis Scores (MFS) of F2/F3: Final Results From the EPIC3 Program
|
| |
| |
Reported by Jules Levin
AASLD Nov 2 2010 Boston
T. Poynard,1 M. Munteanu,2 J. Bruix,3 E. R. Schiff,4 M. Diago,5 T. Berg,6 R. Moreno-Otero,7 L. G. Lyra,8 N. Boparai,9 L. H. Griffel,10 M. Burroughs,9 C. A. Brass,9 J. K. Albrecht9
1APHP UPMC Paris Liver Center, Paris, France; 2BioPredictive, Paris, France; 3Hospital Clinic, University of Barcelona, Barcelona, Spain; 4University of Miami School of Medicine, Miami, FL, USA; 5Hospital General Universitario de Valencia, Valencia, Spain;
6Universitatsklinikum Leipzig, Leipzig, Germany; 7Instituto de Salud Carlos III, Madrid, Spain; 8Hospital Sao Rafael, Salvador, Brazil; 9Schering-Plough Corporation, now Merck & Co., Inc., Whitehouse Station, NJ, USA;
10Former employee of Schering-Plough Corporation, now Merck & Co., Inc., Whitehouse Station, NJ, USA
|
| |
|
|
|
|
|
